1. Home
  2. BCAB vs SMSI Comparison

BCAB vs SMSI Comparison

Compare BCAB & SMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • SMSI
  • Stock Information
  • Founded
  • BCAB 2007
  • SMSI 1982
  • Country
  • BCAB United States
  • SMSI United States
  • Employees
  • BCAB N/A
  • SMSI N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • SMSI Computer Software: Prepackaged Software
  • Sector
  • BCAB Health Care
  • SMSI Technology
  • Exchange
  • BCAB Nasdaq
  • SMSI Nasdaq
  • Market Cap
  • BCAB 19.9M
  • SMSI 16.7M
  • IPO Year
  • BCAB 2020
  • SMSI 1995
  • Fundamental
  • Price
  • BCAB $0.33
  • SMSI $0.70
  • Analyst Decision
  • BCAB Buy
  • SMSI Strong Buy
  • Analyst Count
  • BCAB 2
  • SMSI 1
  • Target Price
  • BCAB $1.00
  • SMSI $5.00
  • AVG Volume (30 Days)
  • BCAB 811.8K
  • SMSI 491.8K
  • Earning Date
  • BCAB 08-11-2025
  • SMSI 08-12-2025
  • Dividend Yield
  • BCAB N/A
  • SMSI N/A
  • EPS Growth
  • BCAB N/A
  • SMSI N/A
  • EPS
  • BCAB N/A
  • SMSI N/A
  • Revenue
  • BCAB $11,000,000.00
  • SMSI $19,378,000.00
  • Revenue This Year
  • BCAB N/A
  • SMSI $10.12
  • Revenue Next Year
  • BCAB N/A
  • SMSI $63.12
  • P/E Ratio
  • BCAB N/A
  • SMSI N/A
  • Revenue Growth
  • BCAB N/A
  • SMSI N/A
  • 52 Week Low
  • BCAB $0.24
  • SMSI $0.52
  • 52 Week High
  • BCAB $2.53
  • SMSI $2.48
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 38.71
  • SMSI 36.18
  • Support Level
  • BCAB $0.33
  • SMSI $0.74
  • Resistance Level
  • BCAB $0.37
  • SMSI $0.82
  • Average True Range (ATR)
  • BCAB 0.04
  • SMSI 0.09
  • MACD
  • BCAB -0.00
  • SMSI -0.03
  • Stochastic Oscillator
  • BCAB 5.26
  • SMSI 9.32

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About SMSI Smith Micro Software Inc.

Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.

Share on Social Networks: